MétaCan
Menu
Back to cohort
Record W4284967068 · doi:10.1038/s41598-022-16151-0

Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

2022· erratum· en· W4284967068 on OpenAlexaff
Alexander G. Bick, Konstantin Popadin, Christian Thorball, Md Mesbah Uddin, Markella V. Zanni, Bing Yu, Matthias Cavassini, Andri Rauch, Philip Tarr, Patrick Schmid, Enos Bernasconi, Huldrych F. Günthard, Peter Libby, Eric Boerwinkle, Paul J. McLaren, Christie M. Ballantyne, Steven Grinspoon, Pradeep Natarajan, Jacques Fellay, Irène A. Abela, Karoline Aebi‐Popp, Αchilles Anagnostopoulos, Manuel Battegay, Dominique L. Braun, Heiner C. Bucher, Alexandra Calmy, Angela Ciuffi, G Dollenmaier, Matthias Egger, Luigia Elzi, Jan Fehr, Hansjakob Furrer, Christoph A. Fux, Anna Hachfeld, David Haerry, Barbara Hasse, Hans H. Hirsch, Matthias Hoffmann, Irène Hösli, M Huber, Christian R. Kahlert, Laurent Kaiser, Olivia Keiser, Thomas Klimkait, Roger D. Kouyos, Helen Kovari, Katharina Kusejko, G Martinetti, Begoña Martínez de Tejada, Catia Marzolini, Karin J. Metzner, N Müller, Johannes Nemeth, Dunja Nicca, P Paioni, G Pantaleo, Matthieu Perreau, Roberto F. Speck, M Stöckle, Alexandra Trkola, Gilles Wandeler, Sabine Yerly

Bibliographic record

VenueScientific Reports · 2022
Typeerratum
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsUniversity of ManitobaPublic Health Agency of Canada
FundersBoston Scientific CorporationXBiotechNational Heart, Lung, and Blood InstituteBrigham and Women's HospitalAstraZenecaAmgen
KeywordsIndeterminateHuman immunodeficiency virus (HIV)HaematopoiesisMedicineVirologyBiologyGerontologyEnvironmental healthGeneticsStem cellMathematics

Abstract

fetched live from OpenAlex

"Dr. Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion, Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Merck, Novartis, Pfizer, Sanofi-Regeneron. Dr. Libby is a member of scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc. Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis. Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr Natarajan reported grants from Amgen during the conduct of the study and grants from Boston Scientific; grants and personal fees from Apple; personal fees from Novartis and MannBlackstone Life Sciences; and other support from Vertex outside the submitted work. None of the authors other than those already mentioned share any competing interests."

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.074
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.023
Threshold uncertainty score0.078

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.074
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0040.002
Science and technology studies0.0030.002
Scholarly communication0.0040.002
Open science0.0030.001
Research integrity0.0090.013
Insufficient payload (model declined to judge)0.0230.013

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.248
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractno

Explore more

Same venueScientific ReportsSame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207